A Two Part, Randomized, Participant and Investigator-blinded, 2-arm, Parallel-design, Placebo-controlled Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles on Tendon Regeneration in Patients With Achilles Tendinopathy
Latest Information Update: 24 Sep 2025
At a glance
- Drugs NGI 226 (Primary)
- Indications Tendon injuries
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 20 Aug 2025 Planned End Date changed from 10 Feb 2026 to 24 Feb 2026.
- 20 Aug 2025 Planned primary completion date changed from 10 Feb 2026 to 24 Feb 2026.
- 11 Jul 2025 Planned End Date changed from 3 Dec 2025 to 10 Feb 2026.